Advertisement
Advertisement
May 8, 2026
Stryker Completes Acquisition of Amplitude Vascular Systems
KEY TAKEAWAYS
- Stryker closes acquisition of Amplitude Vascular Systems, Inc. (AVS).
- AVS is developing a next-generation intravascular lithotripsy platform to treat calcified PAD.
- Acquisition of AVS is intended to strengthen Stryker’s peripheral vascular portfolio by adding revascularization technology.
May 8, 2026—Stryker announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), which is developing a next-generation intravascular lithotripsy platform designed to treat complex peripheral arterial disease. The company recently announced the definitive agreement to acquire AVS.
“This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease,” commented Kevin Lobo, Chair and CEO of Stryker, in the press release. “By integrating AVS’s innovative CO₂-generated pressure wave technology with Stryker’s scale and resources, we are well-positioned to deliver solutions that support physicians and patient outcomes.”
AVS, which is based in Boston, Massachusetts, is focused on treating severely calcified arterial disease. The company was founded in 2017 by Hitinder Gurm, MD, and Robert Chisena, PhD. Dr. Gurm is interventional cardiologist and Chief Clinical Officer at the University of Michigan in Ann Arbor, Michigan. Dr. Chisena is Chief Technical Officer at AVS.
Advertisement
Advertisement
